Oxford BioDynamics PLC (GB:OBD)
LSE:OBD
Want to see GB:OBD full AI Analyst Report?
OBD Stock Chart & Stats
0.24 p
0.04 p(3.63%)
At close: 4:00 PM EST
0.24 p
0.04 p(3.63%)
Day’s Range― - ―
52-Week Range0.17 p - 0.78 p
Previous CloseN/A
Volume22.58K
Average Volume (3M)21.87M
Market Cap
£7.72M
Enterprise Value7.55M
Total Cash (Recent Filing)£1.39M
Total Debt (Recent Filing)£5.11M
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.32M
Bulls Say, Bears Say
Bulls Say
Proprietary EpiSwitch PlatformOBD’s proprietary EpiSwitch technology analyzes 3D chromatin conformations, giving a distinct scientific moat in epigenetic diagnostics. A durable platform can generate recurring service work, enable multiple test indications, and support licensing, providing scalable long-term revenue optionality.
Revenue Growth TrendSustained top-line growth indicates demand for OBD’s tests and services and provides a foundation to drive operating leverage over time. Continued revenue expansion can finance R&D and commercialization, improving odds of converting platform potential into durable, higher-margin products.
Diverse Revenue StreamsMultiple revenue channels—direct test commercialization, fee-for-service biomarker work, and licensing/partnership milestones—reduce single-market dependency. This structural diversification can stabilize cash flows and permit partnerships to underwrite development and market access over the medium term.
Bears Say
Consistent UnprofitabilityChronic negative margins show the business currently cannot convert revenue into profit, implying ongoing need for external capital. Without structural margin improvement through scale, pricing, or cost reduction, loss-making operations threaten long-term viability and investor returns.
High Financial LeverageA very high debt-to-equity ratio raises refinancing and interest burden risks, limiting strategic flexibility. Debt-heavy capital structures constrain investment in commercialization and R&D, and amplify downside if revenue growth slows or margins remain negative.
Weak Cash GenerationDeclining free cash flow and negative operating cash conversion mean the company cannot self-fund expansion and is dependent on external funding. Persistent cash flow weakness increases dilution risk or debt reliance and impedes sustained commercialization and regulatory efforts.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.17 p and its highest was 0.78 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £7.72M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jun 02, 2026 which is in 23 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Currently, no data Available
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---